The in vitro activity of azithromycin against 1,237 nontyphoidal Salmonella enterica isolates collected from Finnish patients between 2003 and 2008 was investigated. Only 24 (1.9%) of the isolates tested and 15 (5.1%) of the 294 isolates with reduced fluoroquinolone susceptibility had azithromycin MICs of >32 g/ml. These data show that azithromycin has good in vitro activity against nontyphoidal S. enterica, and thus, it may be a good candidate for clinical treatment studies of salmonellosis.
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Salmonella is one of the most common causes of food-borne illnesses and a major cause of human infections all over the world (23) . Salmonella infections are usually treated with fluoroquinolones or extended-spectrum cephalosporins. Unfortunately, excessive use of fluoroquinolones both in human and in veterinary medicine has led to increasing numbers of resistant isolates, including nontyphoidal strains of Salmonella enterica (18, 19, 28) . In addition, the nonclassical quinolone resistance phenotype (the Qnr phenotype), showing reduced susceptibility to ciprofloxacin (MIC of Ն0.125 g/ml) but susceptibility or only low-level resistance to nalidixic acid (MIC of Յ32 g/ml), has become more common (6, 14, 19, 20, 22) . Extended-spectrum ␤-lactamase (ESBL) producers have emerged in Enterobacteriaceae and in Salmonella, and there are reports of the coappearance of ESBL and qnr genes in the same transferable genetic elements (5, 10, 21, 27) . These resistance problems may jeopardize the treatment of severe Salmonella infections. Thus, alternative antibiotics for the treatment of Salmonella infections are needed.
Salmonella isolates are intrinsically resistant to erythromycin via active efflux (2) but naturally susceptible to azithromycin (29) , which is a 15-membered erythromycin derivative. Resistance to macrolides is usually conferred by mutations in nucleotides A2058 and A2059 of the 23S rRNA, according to the Escherichia coli numbering (26) . Also, the alteration of the 50S ribosomal subunit proteins L4 (rlpD) and L22 (rlpV) may lead to macrolide resistance (4) .
The purpose of the present study was to determine the in vitro activity of azithromycin against nontyphoidal Salmonella isolates collected between 2003 and 2008 from Finnish patients. Special attention was paid to isolates with reduced fluoroquinolone susceptibility or showing the Qnr phenotype. In addition, mutations in the 23S rRNA and in the L4 and L22 ribosomal proteins were investigated. A total of 1,237 nontyphoidal Salmonella isolates (638 domestic and 599 foreign) collected from Finnish patients between 2003 and 2008 were included in this study. Starting in January each year, we collected the first 100 domestic and the first 100 foreign, i.e., collected from Finnish travelers returning from abroad, Salmonella isolates. The strains were serotyped at the National Salmonella Reference Centre in Finland.
The MICs of antimicrobial agents for the isolates were determined by the agar dilution method according to the CLSI guidelines (8) . Mueller-Hinton II agar (Becton Dickinson, Cockeysville, MD) was used as the culture medium. All 1,237 Salmonella isolates were tested for susceptibility to ciprofloxacin, nalidixic acid, and azithromycin (all from Sigma, Steinheim, Germany). We tested 809 selected isolates for erythromycin (Sigma) and 635 for telithromycin (Sanofi Aventis, Paris, France) susceptibility. Control strains for susceptibility testing were as described previously (14) . On the basis of earlier publications (1, 16, 17) , the MIC breakpoint chosen for reduced ciprofloxacin susceptibility was Ն0.125 g/ml. For nalidixic acid, CLSI breakpoints were used (9) . Based on the EUCAST recommendation for S. enterica serovar Typhi (www.eucast .org) and a previous publication (3), the epidemiological cutoff value chosen for azithromycin was Ն32 g/ml. The susceptibility data were analyzed by using the WHONET 5.4 computer program.
Pyrosequencing was used to detect macrolide resistance causing point mutations in the ribosomal target sites A2058 and A2059 (E. coli numbering) of the 23S rRNA in 22 isolates with azithromycin MICs of Ն32 g/ml, 44 isolates belonging to the Qnr phenotype, and 73 isolates showing erythromycin MICs of Ն32 g/ml. Pyrosequencing was performed with previously described primers and protocols (15) using a PSQ 96MA pyrosequencer.
The 50S ribosomal proteins L4 and L22 were amplified, and mutations were screened in 24 isolates having azithromycin MICs of Ն32 g/ml, of which 6 were of the Qnr phenotype. In addition, 13 isolates having only erythromycin MICs of Ն32 g/ml and showing the Qnr phenotype were tested. DNA was prepared as described above. The specific primers used for amplification of the complete L4 and L22 genes rlpD and rlpV were Salm_L4_f (5Ј-TGAAGGCGTAAGGGGATAGCA-3Ј) and Salm_L4_r (5Ј-TCAGCAGA CGTTCTTCACGAA-3Ј) and Salm_L22_f (5Ј-GAAATAAGGTAG GAGGAAGAG-3Ј) and Salm_L22_r (5Ј-CCATTGCTAGTCTCCAGAGTC-3Ј). The PCR conditions were as follows: 94°C for 10 min, 94°C for 30 s, 56°C for 30 s, and 72°C for 60 s for 33 cycles. Any L4-or L22-positive results were confirmed by direct sequencing of both strands of amplicons using specific PCR primers as previously described (24). Amino acid sequences were then compared with the known rlpD and rlpV genes by a BLAST search through the European Bioinformatics Institute (http://www.ebi .ac.uk/Tools/blast/). Two different populations of S. enterica were detected regarding the azithromycin MIC distribution. The majority of the isolates had azithromycin MICs of 4 to 8 g/ml, i.e., representing the wild-type population, whereas a minority of the isolates had MICs of 32 to Ն128 g/ml, i.e., over the epidemiological cutoff value. Between 2003 and 2008, 24 (1.9%) of the 1,237 isolates had azithromycin MICs of Ն32 g/ml ( Fig. 1; Table 1 ). Nine (1.4%) of the 638 domestic isolates and 15 (2.1%) of the 599 foreign isolates had azithromycin MICs over the epidemiological cutoff value.
Two hundred ninety-four (23.8%) S. enterica isolates showed reduced fluoroquinolone susceptibility, and 53 (18.0%) of them showed the Qnr phenotype. Among the isolates with reduced fluoroquinolone susceptibility, 4 (5.2%) domestic and 11 (5.1%) foreign isolates had azithromycin MICs of Ն32 g/ml. Among the Qnr phenotype isolates, six (11.3%) had azithromycin MICs of Ն32 g/ml (Table 1) . Azithromycin MICs of Ն32 g/ml were detected among 12 different serovars, S. enterica serovar Stanley being the most common one, and all isolates with a Qnr phenotype belonged to S. enterica serovar Stanley (Table 1) .
Of the S. enterica isolates tested, 99.6% (806/809) had erythromycin MICs of Ն32 g/ml. The erythromycin MICs varied between 8 and Ն128 g/ml, and the vast majority of the isolates had erythromycin MICs of Ն64 g/ml (Fig. 1) .
No mutations in A2058 or A2059 of the 23S rRNA gene were detected among any of the isolates tested. Sequencing of the 50S ribosomal proteins L4 and L22 revealed G235A and C379T mutations in the rlpD gene and G25A in the rlpV gene, Table 2 ). An Arg127-Trp substitution in the rlpD gene was found in three S. enterica serovar Montevideo isolates, which also had an Asp9-Asn substitution outside the coding region (Table 2) . Salmonella isolates are intrinsically resistant to erythromycin via the AcrAB efflux pump (2) but naturally susceptible to azithromycin (29) . Azithromycin has shown good efficacy in the treatment of patients suffering from typhoid fever (7, 12, 13, 25, 30) , and there has been speculation that azithromycin could be used for empirical therapy of traveler's diarrhea (11, 31) . The present study was performed to determine the in vitro activity of azithromycin toward nontyphoidal Salmonella isolates collected from Finnish patients between 2003 and 2008. Our results show that while nearly all (99.6%) of our S. enterica isolates had erythromycin MICs of Ն32 g/ml, only 24 isolates had azithromycin MICs of Ն32 g/ml. Azithromycin showed good in vitro efficacy also against S. enterica isolates with reduced fluoroquinolone susceptibility, although 11.3% of the Qnr phenotype isolates showed azithromycin MICs of Ն32 g/ml.
These data show that azithromycin has good in vitro activity against nontyphoidal S. enterica isolates. Although highly azithromycin-resistant isolates did occur, azithromycin was effective even against the isolates with reduced fluoroquinolone susceptibility, including those showing the Qnr phenotype. Based on these results, azithromycin is a good candidate for clinical treatment studies of salmonellosis. 
